LUNG CANCER RELATED SPILLOVER EFFECT ON FAMILY MEMBER’S HEALTH-RELATED QUALITY OF LIFE: A US-BASED EMPIRICAL ANALYSIS
Author(s)
Suning Zhao, MPH, Ruixi Yu, MA, Boshen Jiao, MPH, PhD;
University of Southern California, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Los Angeles, CA, USA
University of Southern California, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Los Angeles, CA, USA
OBJECTIVES: Lung cancer may affect not only patients but also their family members, through caregiving responsibilities, psychological distress, and financial strain. This effect intensifies as patient health declines. Therefore, incorporating family spillover effects into cost-effectiveness analyses (CEAs) is important for capturing the full value of interventions. However, empirical estimates specific to lung cancer remain limited. This study estimates family members’ health related quality of life (HRQoL) loss as a function of patients’ HRQoL decline.
METHODS: We leveraged data from the Medical Expenditure Panel Survey from 2003 to 2023 to construct a panel dataset of lung cancer patients and their family members. Family members of individuals without cancer served as the control group. HRQoL was measured using EQ-5D values derived via the time trade-off method, visual analogue scale (VAS) and SF-6D values derived via standard gamble. Beta regression models were employed to assess the association between family members’ HRQoL and cancer status, patient HRQoL scores, age categories, adjusting for demographic characteristics. The fitted regression model was then used to predict family HRQoL loss across varying levels of patient HRQoL loss.
RESULTS: Spillover effects increased as lung cancer patients’ HRQoL loss arouse. For EQ-5D, at a patient loss of 0.1, family member’s loss was 0.094[95% CI: 0.0892-0.0995]; when patient loss reached 0.6, family member’s EQ-5D loss increased to 0.1846[95% CI: 0.1953-0.1740]. For SF-6D, family member’s SF-6D loss was 0.003[95% CI: 0.0030-0.0039] at patient loss 0.1 and 0.0586[95% CI: 0.0573-0.0600] at patient loss 0.6. For VAS, when a patient’s VAS loss was 0.1, the corresponding family member’s loss was 0.0728[95% CI: 0.0713-0.0742]; when patient VAS loss reached 0.6, family member’s loss increased to 0.1306[95% CI: 0.1280-0.1332].
CONCLUSIONS: This study provides key estimates for integrating family spillover effects into CEAs for cancer interventions, enabling a more comprehensive evaluation of their societal value.
METHODS: We leveraged data from the Medical Expenditure Panel Survey from 2003 to 2023 to construct a panel dataset of lung cancer patients and their family members. Family members of individuals without cancer served as the control group. HRQoL was measured using EQ-5D values derived via the time trade-off method, visual analogue scale (VAS) and SF-6D values derived via standard gamble. Beta regression models were employed to assess the association between family members’ HRQoL and cancer status, patient HRQoL scores, age categories, adjusting for demographic characteristics. The fitted regression model was then used to predict family HRQoL loss across varying levels of patient HRQoL loss.
RESULTS: Spillover effects increased as lung cancer patients’ HRQoL loss arouse. For EQ-5D, at a patient loss of 0.1, family member’s loss was 0.094[95% CI: 0.0892-0.0995]; when patient loss reached 0.6, family member’s EQ-5D loss increased to 0.1846[95% CI: 0.1953-0.1740]. For SF-6D, family member’s SF-6D loss was 0.003[95% CI: 0.0030-0.0039] at patient loss 0.1 and 0.0586[95% CI: 0.0573-0.0600] at patient loss 0.6. For VAS, when a patient’s VAS loss was 0.1, the corresponding family member’s loss was 0.0728[95% CI: 0.0713-0.0742]; when patient VAS loss reached 0.6, family member’s loss increased to 0.1306[95% CI: 0.1280-0.1332].
CONCLUSIONS: This study provides key estimates for integrating family spillover effects into CEAs for cancer interventions, enabling a more comprehensive evaluation of their societal value.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE270
Topic
Economic Evaluation
Topic Subcategory
Novel & Social Elements of Value, Work & Home Productivity - Indirect Costs
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology